How can we help?

MAMMALIAN CELL TECHNOLOGY

Bioneer assists clients in the pre-clinical and early clinical phases with production of recombinant proteins in a variety of mammalian cell systems, with access to existing or development of novel functional assays based upon mammalian cells as well as general technology development, e.g. bioreactor evaluation, biobanking, and cell handling. In fact, we can support our clients in the entire process of bringing a novel biologic compound from the laboratory through pre-clinical evaluation for functionality and safety.

IMMUNE TARGETING

Bioneer offers evaluation of compounds using mainly three cell systems 1) Primary dendritic cells (human and murine) 2) Peripheral blood mononuclear cells (PBMCs) and 3) cell line based models. We provide services in our model systems in the discovery process (mainly evaluation of mechanism of action and immune modulation and suppression of specific inflammatory responses) as well as activities involved in the development process (mainly evaluation of safety of IV administered drugs, and assessment of potency).

PROTEIN MANUFACTURING

Bioneer addresses a client's needs for limited amounts of recombinant proteins, e.g. during the discovery phase and preclinical phase of biologics development.

DRUG DEVELOPMENT

Turning an active compound into a drug product

Pharmaceutical services, covering the field from lead identification to final formulation of the active compound, are provided by Bioneer:FARMA.

Bioneer:FARMA is a business unit of Bioneer established in collaboration with the Faculty of Pharmaceutical Sciences (FARMA), University of Copenhagen, Denmark.

BIOMARKERS

Bioneer offers a range of services related to the identification, validation and documentation of disease relevant biomarkers and drug targets. These services comprise a toolbox of molecular methods that will facilitate the pre-clinical development of both biomarkers, drug-targets and active compounds, which will be useful in diagnostic, prognostic, and therapeutic contexts, and, furthermore, serve as effective means to optimize clinical trial designs.

DYNAMIC GASTRIC MODEL

The Dynamic Gastric Model is the first true "dynamic" in-vitro model of the human stomach that fully replicates the complex biochemical conditions and the array of gastric forces crucial for the prediction of oral pharmaceuticals and food products

News:

2017-07-04:
"Great pleasure to be back" - Kirsten Drejer, New Chairman of the Bioneer Board

Bioneer is happy to announce that Kirsten Drejer, co-founder and former CEO of Symphogen has accepted to chair the Board of Directors at Bioneer from early spring 2017.

Read more
2017-06-14:
Unanticipated Immune Responses Of Biopharmaceuticals

Understanding the interplay between biopharmaceuticals and the human immune system is of increasing importance. Find out more about Bioneer’s knowhow and experience in the field in the new DANSK BIOTEK magazine. 

Read more
2017-03-29:
A Fast Track To A Recombinant Biologic
In the latest edition of DANSK BIOTEK Bioneer has published a retrospective article about the evolution of recombinant protein production.  
Read more
READ MORE NEWS

Meet us at:

Nordic Life Science Days, September 12-14, 2017

The largest Nordic partnering conference dedicated to the life science industry is coming to the Medicon Valley region. Bioneer looks forward to greeting Nordic and international attendees at booth A02.

Read more
15th Euro Fed Lipid Congress, August 27-30, 2017

Oil, Fats and Lipids - the topic of the congress and a few of Bioneer:FARMA's favorite substances. Meet Bioneer:FARMA in Uppsala and get the opportunity to discuss your oily projects.

Read more
Other places to meet us